WilmerHale Successfully Represents Fabre-Kramer Pharmaceuticals in Collaboration with GlaxoSmithKline

WilmerHale Successfully Represents Fabre-Kramer Pharmaceuticals in Collaboration with GlaxoSmithKline

Client News

Related Solutions

We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

WilmerHale successfully represented its client Fabre-Kramer Pharmaceuticals in its worldwide development and commercialization agreement with GlaxoSmithKline for Fabre-Kramer's gepirone ER product, a 5HT1a agonist expected to be submitted in the first quarter of 2007 for FDA review in the US for major depressive disorder (MDD). Under the terms of the agreement, Fabre-Kramer Pharmaceuticals will receive an upfront cash payment followed by additional development and commercialization milestone payments and double-digit percentage royalty payments on worldwide sales of gepirone ER and follow-on products. In return, GlaxoSmithKline was granted an exclusive, worldwide license to develop, manufacture and commercialize gepirone ER and follow-on products.

The WilmerHale lawyers working on the transaction included David Redlick, Steven Barrett, Allison May and James Czaban.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel